Exosomal miRNAs in hepatocellular carcinoma development and clinical responses

Table 2 Clinical significance of exosomal miRNAs in HCC

Clinical significance	Exosomal miRNAs	Source	Expression in HCC	Clinical relevance	Ref.
Detection and diagnosis	miR-665	Serum	Up	Higher in HCC than the healthy and associated with HCC progression	[32]
	miR-18a, miR-221, miR-222, miR-224	Serum	Up	Distinguishes HCC from CHB or LC	[34]
	miR-21	Serum	Up	Higher in HCC than in CHB and in healthy volunteers	[35]
	miR-101, miR-106b, miR-122, miR-195	Serum	Down	Distinguishes HCC from CHB or LC	[34]
	miR-9-3p	Serum	Down	Lower levels in HCC than in healthy donors	[36]
Detection, prognosis and recurrence	miR-638	Serum	Down	Predicts poor prognosis in HCC patients	[33]
	miR-125b	Serum	Down	Lower levels of exosomal miR-125b correlated with shorter time to recurrence and reduced overall survival	[38]
	miR-718	Serum	Down	Poor prognosis and high rate of recurrence after liver transplantation	[37]
Potential treatment	miR-122	Cells	Down	Renders HCC cells more sensitive to chemotherapeutic agents and improves the anti-tumor effect of sorafenib on HCC in vivo	[43]
Potential treatment	miR-335-5p	Cells	Down	Inhibits recipient cell proliferation and tumor growth in vivo	[18]

Exosomal miRNAs as biomarkers can be used for detection, diagnosis, prognosis, and recurrence and can be a potential treatment of HCC
HCC hepatocellular carcinoma, CHB chronic hepatitis, LC liver cirrhosis

ISSN: 1756-8722